Filing Flows › Janux Therapeutics (JANX) › Q3 2026 › vs Q2 2026
Janux Therapeutics (JANX) Q3 2026 vs Q2 2026 (quarter over quarter)
Janux Therapeutics's revenue fell $978K (-10%) from $10.3M in Q2 2026 to $9.3M in Q3 2026.
Janux Therapeutics, Q3 2026: revenue $9.3M (-7% year over year), operating margin -336.5%, net loss $21.6M, operating cash flow −$25.2M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $9.3M | $10.3M | −$978K | -10% |
| Other income, net | $9.7M | $9.7M | −$30K | -0.3% |
| Net loss | $21.6M | $22.0M | −$402K | -2% |
| Costs & expenses | $40.5M | $42.0M | −$1.4M | -3% |
| Operating costs | $40.5M | $42.0M | −$1.4M | -3% |
| Research & development | $30.6M | $31.0M | −$429K | -1% |
| General & admin | $10.0M | $11.0M | −$981K | -9% |
| Operating cash sources | $34.2M | −$3.0M | $37.1M | — |
| Depreciation | $458K | $463K | −$5K | -1% |
| Share-based compensation | $8.5M | $9.1M | −$527K | -6% |
| Cash used in operations | $25.2M | −$12.5M | $37.7M | — |
| Net loss absorbed | $21.6M | $22.0M | −$402K | -2% |
| Working capital & other | $12.6M | −$24.9M | $37.5M | — |
Questions
How much did Janux Therapeutics's revenue grow quarter over quarter in Q3 2026?
Janux Therapeutics's revenue fell $978K (-10%) from $10.3M in Q2 2026 to $9.3M in Q3 2026.